MedTrace Logo

Phase I Study of Kukoamine B Mesilate in Healthy Volunteers

NCT02219971 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2017-05-03

No results posted yet for this study

Summary

The purpose of this study is to assess safety, tolerance and pharmacokinetics of a single intravenous injection Kukoamine B Mesilate in health volunteer

Conditions

  • Healthy

Interventions

DRUG

Kukoamine B Mesilate

Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Sponsors & Collaborators

  • Southwest Hospital, China

    collaborator OTHER

  • Tianjin Chasesun Pharmaceutical Co., LTD

    lead INDUSTRY

Principal Investigators

  • SHUAI CHEN · TIAN JIN CHASE SUN PHARMACEUTICAL CO.,LTD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-05-06
Completion
2015-05-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02219971 on ClinicalTrials.gov